Strains vary season to season7
In the postvaccination era, several rotavirus strains have been prevalent in the US.
![In 2006, G1P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 193](https://www.merckvaccines.com/wp-content/uploads/sites/8/2021/02/2006-updated.svg "In 2006, G1P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 193")
![In 2007, G1P[8] and G12P[8] Were Shown to Be the Most Prevalent Rotavirus Strains in a Surveillance Study With a Sample Size of 232](https://www.merckvaccines.com/wp-content/uploads/sites/8/2021/02/2007.svg "In 2007, G1P[8] and G12P[8] Were Shown to Be the Most Prevalent Rotavirus Strains in a Surveillance Study With a Sample Size of 232")
![In 2008, G1P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 26](https://www.merckvaccines.com/wp-content/uploads/sites/8/2021/02/2008.svg "In 2008, G1P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 26")
![In 2011, G3P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 80](https://www.merckvaccines.com/wp-content/uploads/sites/8/2021/02/2011.svg "In 2011, G3P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 80")
![In 2012, G12P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 2](https://www.merckvaccines.com/wp-content/uploads/sites/8/2021/02/2012.svg "In 2012, G12P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 2")
![In 2013, G12P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 102](https://www.merckvaccines.com/wp-content/uploads/sites/8/2021/02/2013.svg "In 2013, G12P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 102")
![In 2015, G12P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 118](https://www.merckvaccines.com/wp-content/uploads/sites/8/2021/02/2015.svg "In 2015, G12P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 118")
![In 2016, G12P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 23](https://www.merckvaccines.com/wp-content/uploads/sites/8/2021/02/2016.svg "In 2016, G12P[8] Was Shown to Be the Most Prevalent Rotavirus Strain in a Surveillance Study With a Sample Size of 23")
aThe New Vaccine Surveillance Network (NVSN) conducted active surveillance for hospitalization and visits to the emergency department due to acute gastroenteritis in children <3 years of age from 3 US counties during the 2006 to 2016 seasons. Among 6,954 whole stool specimens collected, 928 tested positive for rotavirus and were submitted to the CDC for genotyping.
Mixed, mixed genotypes; n, number of samples genotyped; NT, non-typeable genotypes.
CDC, Centers for Disease Control and Prevention.
Reference
Indications and Usage for RotaTeq
RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.
Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.
RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.
Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.
Infants with a history of intussusception should not receive RotaTeq.
No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.
In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.
No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.
Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.
In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.
In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.
RotaTeq may not protect all vaccine recipients against rotavirus.
Before administering RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent), please read the accompanying Prescribing Information. The Patient Product Information also is available.